Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 556 to 570 of 694 results for end of life care

  1. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

  2. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.

  3. Child abuse and neglect (NG76)

    This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.

  4. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  5. Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.

  6. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

  7. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

  8. Methods for the development of NICE public health guidance (third edition) (PMG4)

    This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

  9. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

  10. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.

  11. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  12. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  13. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

  14. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

    Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.

  15. Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.